A Novel Analysis of the Pfizer Trial: Vaccine Effectiveness Was Nowhere Near 95%

 A veteran researcher with over 200 publications claims to have uncovered evidence that the true efficacy of the Pfizer COVID-19 vaccine against symptomatic infection was dramatically overstated in the original 2021 trial (NEJM paper that reported ~95%).

Using publicly available Pfizer trial documents (especially the “Final Full Clinical Study Report” submitted to the FDA), the author focuses on the brief window between Dose 2 and 1 month later, when both symptomatic and asymptomatic (anti-N antibody–detected) infection data exist.

He makes two core assumptions (both now widely accepted):

1. The vaccine does not prevent infection; it only reduces symptoms once infected.
2. Anti-N antibody testing severely under-detects post-vaccination infections (by a factor of 2–3×, based on independent studies of Pfizer and Moderna vaccines).

After correcting for this under-detection of asymptomatic infections in the vaccinated arm, the reported 50–60% efficacy against asymptomatic infection disappears or even reverses (corrected risk ratio 1.0–1.5).

Using a simple statistical relationship between risk ratios and odds ratios for complementary outcomes (symptomatic vs. asymptomatic), plus literature-based estimates that 30–50% of infections are asymptomatic, he back-calculates what the efficacy against symptomatic infection must have been if the asymptomatic data are correct and the symptomatic case counts are unreliable.

Across multiple plausible scenarios, the estimated true vaccine effectiveness against symptomatic COVID-19 ranges from 0% to a maximum of ~25% (most calculations cluster below 25%) — far lower than the 95% originally reported and before any waning.

The legendary 95% figure was an artifact of biased case ascertainment (missing many mild/symptomatic cases in the vaccinated arm) and flawed serology testing. A corrected, indirect estimate using only the more trustworthy asymptomatic infection endpoint suggests the vaccine’s real-world ability to prevent symptomatic disease was modest at best, even at peak immunity shortly after Dose 2.

The author believes these findings are so explosive that no mainstream biomedical journal would publish them, despite the analysis being methodologically straightforward and based entirely on Pfizer’s own trial documents.

https://brownstone.org/articles/a-novel-analysis-of-the-pfizer-trial-vaccine-effectiveness-was-nowhere-near-95/